A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity

Cancer Science

Volumn 96, Issue 9, 2005, Pages 614-619

  Aoyagi, Yoshimi ^a   Masuko, Norio ^a   Ohkubo, Shuichi ^a   Kitade, Makoto ^a   Nagai, Kentaro ^a   Okazaki, Shinji ^a   Wierzba, Konstanty ^a   Terada, Tadafumi ^a   Sugimoto, Yoshikazu ^a   Yamada, Yuji ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[4 (TERT BUTYL)PHENYL]METHYLTHIO] 3 [4 [2 [1 (4 CHLOROPHENYL) 5 METHYLPYRAZOL 4 YL]ETHOXY]PHENYL] 2 PROPENOIC ACID; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CINNAMIC ACID DERIVATIVE; CISPLATIN; CYCLIN DEPENDENT KINASE 2; FLUOROURACIL; PROTEIN TYROSINE PHOSPHATASE; RETINOBLASTOMA PROTEIN; TPY 835; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL POPULATION; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INHIBITION KINETICS; LUNG CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CDC25 PHOSPHATASE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; G1 PHASE; HUMANS; KINETICS; LUNG NEOPLASMS; PHOSPHORYLATION; PYRAZOLES; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED;

EID: 27144524029     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00086.x     Document Type: Article

References (32)

1. Bulavin DV, Higashimoto Y, Popoff IJ et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 2001; 411: 102-7.
2. Mailand N, Falck J, Lukas C et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000; 288: 1425-9.
3. Galaktionov K, Lee AK, Eckstein J et al. CDC25 phosphatases as potential human oncogenes. Science 1995; 269: 1575-7.
4. Gasparotto D, Maestro R, Piccinin S et al. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res 1997; 57: 2366-8.
5. Kudo Y, Yasui W, Ue T et al. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res 1997; 88: 947-52.
6. Wu W, Fan YH, Kemp BL, Walsh G, Mao L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res 1998; 58: 4082-5.
7. Dixon D, Moyama I, King MJ. Elevated expression of the cdc25A protein phosphatase in colon cancer. Exp Cell Res 1998; 240: 236-43.
8. Garner-Hamrick PA, Fisher C. Antisense phosphorothioate oligonucleotides specifically down-regulate cdc25B causing S-phase delay and persistent antiproliferative effects. Int J Cancer 1998; 76: 720-8.
9. Lazo JS, Nemoto K, Pestell KE et al. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol 2002; 61: 720-8.
10. Imoto M, Kakeya H, Sawa T et al. Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. I. Taxonomy, isolation, and characterization. J Antibiot 1993; 46: 1342-6.
11. Horiguchi T, Nishi K, Hakoda S, Tanida S, Nagata A, Okayama H. Dnacin A1 and dnacin B1 are antitumor antibiotics that inhibit cdc25B phosphatase activity. Biochem Pharmacol 1994; 48: 2139-41.
12. Otani T, Sugimoto Y, Aoyagi Y et al. New Cdc25B tyrosine phosphatase inhibitors, nocardiones A and B, produced by Nocardia sp. TP-A0248: taxonomy, fermentation, isolation, structural elucidation and biological properties. J Antibiot 2000; 53: 337-44.
13. Sohn J, Kiburz B, Li Z et al. Inhibition of cdc25 phosphatase by indolydihydroxyquinones. J Med Chem 2003; 46: 2580-58.
14. Hamaguchi T, Sudo T, Osada H. RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G1phase. FEBS Lett 1995; 372: 54-8.
15. Tamura K, Rice RL, Wipf P, Lazo JS. Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor. Oncogene 1999; 18: 6989-96.
16. Wu FYH, Sun TP. Vitamin K3 induces cell cycle arrest and cell death by inhibiting cdc25 phosphatase. Eur J Cancer 1999; 35: 1388-93.
17. Carr BI, Wang Z, Wang M et al. A cdc25A antagonizing K vitamin inhibits hepatocyte DNA synthesis in vitro and in vivo. J Mol Biol 2003; 326: 721-35.
18. Utsugi T, Aoyagi K, Asao T et al. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res 1997; 88: 992-1002.
19. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 1992; 11: 3995-4005.
20. Gabrielli BG, Clark JM, McCormack AK, Ellem KA. Ultraviolet light-induced G2 phase cell cycle checkpoint blocks cdc25-dependent progression into mitosis. Oncogene 1997; 15: 749-58.
21. Alessi F, Quarta S, Savio M et al. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblast in G1 phase by specific inhibition of cdk2 kinase activity. Exp Cell Res 1998; 245: 8-18.
22. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci USA 1999; 96: 1002-7.
23. Yoo YD, Choi JY, Lee SJ et al. TGF-beta-induced cell-cycle arrest through the p21 (WAF1/CIP1)-G1 cyclin/Cdks-p130 pathway in gastric-carcinoma cells. Int J Cancer 1999; 83: 512-7.
24. Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 2000; 17: 277-83.
25. Ohmori T, Morikage T, Sugimoto Y et al. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Jpn J Cancer Res 1993; 84: 83-92.
26. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990; 50: 6925-30.
27. Takahashi M, Dodo K, Sugimoto Y et al. Synthesis of the novel analogues of dysidiolide and their structure-activity relationship. Bioorg Med Chem Lett 2000; 10: 2571-4.
28. Tamura K, Pestell K, Donovan P, Lazo J. Elevated cytoplasmic Cdk1 expression and increased bleomycin sensitivity in Cdc25B null mouse embryonic fibroblast. In: The Proceedings of the 60th Annual Meeting of the Japanese Cancer Association. Tokyo: Japanese Cancer Association, 2001.
29. Chen MS, Hurov J, White LS, Woodford-Thomas T, Piwnica-Worms H. Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase. Mol Cell Biol 2001; 21: 3853-61.
30. Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF. Human cdc25A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Report 2000; 1: 71-9.
31. Fuhrmann G, Leisser C, Rosenberger G et al. Cdc25A phosphatase suppresses apoptosis induced by serum derivation. Oncogene 2001; 20: 4542-53.
32. Zou Z, Tsutsui T, Ray D et al. The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21: 4818-28.